Objective-Diabetic hypertriglyceridemia is thought to be primarily driven by increased hepatic de novo lipogenesis.
D yslipidemia is a major risk factor for cardiovascular disease in both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). 1, 2 Diabetic dyslipidemia is associated with high plasma triglycerides, low high-density lipoprotein cholesterol and increased small dense low-density lipoprotein-cholesterol particles. 3 According to a National Health and Nutrition Examination Survey, >30% of people with T2DM have triglyceride levels >2.258 mmol/L (200 mg/ dL). 4 Patients with T1DM also have increased triglycerides levels, especially with poor glucose management. 1 Possible causes of hypertriglyceridemia in patients with diabetes mellitus are increased hepatic very-low-density lipoprotein (VLDL) production or defective removal of triglyceride-rich lipoproteins (chylomicrons and VLDL).
Several rodent models have been developed to explain the relationship between insulin actions and triglycerides. It has been postulated that hyperinsulinemia associated with T2DM drives hepatic de novo triglyceride synthesis via induction of sterol response element-binding protein-1c. 5 Consistent with this hypothesis, lack of insulin action in the liver because of ablation of hepatic insulin receptors and Akt deficiency in mice prevented hepatic triglycerides production, reduced liver triglycerides secretion and led to low circulating triglyceride levels. [6] [7] [8] According to this hypothesis, humans with poorly managed T1DM should show reduced hepatic triglycerides production and plasma triglyceride levels. Likewise, insulin therapy in T2DM should also drive greater liver triglycerides production. However, the opposite has been found: in fact, plasma triglyceride concentrations are increased in patients with T1DM. 9, 10 Moreover, treatment of T2DM patients with insulin results in systemic hyperinsulinemia, but reduced triglyceride levels and decreased hepatic lipid accumulation. 11 Studies in diabetic rodents also conflict with conclusions derived from mice with genetic modifications in the insulin-signaling pathway. Viral destruction of pancreatic islet cells in mice leads to hypertriglyceridemia 12 and refeeding of insulin-deficient mice increased lipogenic gene expression, suggesting that regulation of de novo synthesis is independent of insulin. 13 These data suggest that diabetic hypertriglyceridemia is not primarily caused by defective insulin signaling leading to increased hepatic fatty acid synthesis. The objective of this study was specifically to determine whether the effects of impaired insulin signaling on hepatic triglycerides production found with genetic modifications were also evident in mice with insulin deficiency.
In this report, we show that insulin deficiency in mice leads to increased plasma triglyceride levels and defective removal of postprandial triglycerides. This type of diabetic hypertriglyceridemia was not associated either with reduced mRNA levels of de novo triglyceride synthesis-related genes or with decreased hepatic triglycerides production. Lipoprotein lipase (LpL) mRNA was significantly reduced in skeletal muscle, white adipose tissue (WAT), and heart. Furthermore, LpL activity was decreased in skeletal muscle, brown adipose tissue, and heart. In addition, diabetes mellitus further increased plasma triglycerides in animals with a genetic LpL defect. Our data support human studies and suggest that significant hypertriglyceridemia in insulin-deficient diabetes mellitus is primarily because of changes in lipolysis and substrate return to the liver signaling.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Streptozotocin-Induced Diabetes Mellitus Causes Hypertriglyceridemia in Mice
Two weeks after induction of insulin deficiency by intraperitoneal streptozotocin administration, diabetic mice displayed marked hyperglycemia (6.66±0.5 versus 25.55±0.72 mmol/L; Table 1A ). Concomitantly, these mice had significantly elevated plasma triglyceride levels (1.42±0.09 versus 0.82±0.03 mmol/L in nondiabetic mice). Hypertriglyceridemia persisted after 6 weeks of streptozotocin diabetes mellitus (1.99±0.18 versus 0.91±0.06 mmol/L). In contrast, total plasma cholesterol levels and high-density lipoprotein cholesterol did not change at either time point. As expected, streptozotocindiabetic mice lost weight compared with nondiabetic control animals. Changes in triglycerides were largely caused by increased VLDL triglycerides (1.33±0.09 versus 0.71±0.02 mmol/L; Table 1B ). Plasma free fatty acid (FFA) were increased at both 3 and 6 weeks. Note that the baseline plasma FFA levels were higher in older mice. Plasma FFA showed a positive correlation with plasma triglyceride levels in streptozotocin-diabetic mice, whereas plasma FFA and triglycerides did not significantly correlate with body weight (online-only Data Supplement IA-IC).
Insulin Deficiency Does Not Change Hepatic De Novo Lipogenesis and Hepatic Triglyceride Secretion
To assess whether insulin deficiency and circulating glucose levels affect hepatic triglycerides production, we quantified triglycerides secretion in mice treated with streptozotocin and a lipase inhibitor, P407. Streptozotocin-induced diabetes mellitus did not alter triglycerides secretion compared with nondiabetic wild-type controls ( Figure 1A ). In line with this, hepatic gene expression of de novo lipogenesis genes (Fasn, Acc1, Dgat2, Scd1, Elovl6) showed no significant difference between the diabetic mice and healthy controls after 3 and 8 weeks ( Figure 1B ; online-only Data Supplement ID). Triglycerides content in the liver was decreased ( Figure 1C ; online-only Data Supplement IE), which was likely because of increased β-oxidation as indicated by increased gene expression of the rate limiting enzyme CPT1α ( Figure 1B ; online-only Data Supplement ID). Thus, hypertriglyceridemia in insulin-deficient mice is not caused by increased de novo lipogenesis and hepatic triglycerides secretion.
Hyperglycemia Does Not Drive Hypertriglyceridemia
Excess glucose in diabetes mellitus can be a substrate for hepatic de novo lipogenesis, thereby contributing to diabetic hypertriglyceridemia. 14 To study if hyperglycemia drives hypertriglyceridemia, we treated control and streptozotocindiabetic mice with the glucose-lowering agent dapagliflozin for 3 weeks. Dapagliflozin selectively inhibits the sodium glucose cotransporter 2 in the kidney, thereby increasing urinary glucose excretion and decreasing plasma glucose levels without affecting insulin levels in streptozotocin-diabetic mice as shown before15 and in our study ( Figure 2D ). Insulin levels in dapagliflozin-treated control mice are reduced likely because of the reduction in circulating glucose levels. Despite a significant reduction in plasma glucose levels in streptozotocindiabetic mice neither plasma triglyceride levels (Figure 2A & 2B) nor triglycerides secretion ( Figure 2C ) decreased. Similar to the pharmacological approach, an antisense oligonucleotide against sodium glucose cotransporter 2 did not decrease plasma triglyceride levels in both control and streptozotocin-diabetic mice over the course of 4 weeks (online-only Data Supplement II). These studies suggest that diabetic hypertriglyceridemia is not driven by excess glucose.
Insulin Deficiency Leads to Increased Postprandial Lipemia
As hepatic de novo lipogenesis and triglycerides secretion did not seem to contribute substantially to hypertriglyceridemia, we explored whether defective peripheral lipolysis is the culprit for increased plasma triglyceride levels. After an olive oil gavage, streptozotocin-diabetic mice displayed markedly higher plasma triglyceride levels followed by delayed clearance of plasma triglycerides compared with that of controls ( Figure 3A ). LpL mRNA levels were significantly reduced in skeletal muscle, WAT, and heart after 3 weeks of diabetes mellitus ( Figure 3B ). At 8 weeks, skeletal muscle LpL was reduced and tended to decrease in the WAT and heart of these mice (online-only Data Supplement IIIA). However, mRNA levels of LpL do not always reflect LpL activity because LpL is regulated at transcriptional, translational, and posttranslational levels. 15, 16 Heparin-releasable LpL activity in the heart, brown adipose tissue, and skeletal muscle was significantly reduced in streptozotocin-diabetic mice ( Figure 3C ); there was no change in heparin-releasable activity of hepatic lipase and hepatic lipase mRNA in the liver (online-only Data Supplement IIIB and IV). Hepatic mRNA expression of the LpL-regulating proteins angiopoietin-like 3, 4, and 8 (Angptl 3, 4, and 8) and apolipoproteins apoA-V, ApoB, and ApoC-III were not significantly altered at both 3 and 8 weeks. We also did not detect significant changes of Angptl4, lipase maturation factor 1 and glycosylphosphatidylinositol-anchored highdensity-binding protein 1 in the skeletal muscle ( Figure IV in the online-only Data Supplement). However, we did find an increase in apoC-III in the plasma of streptozotocin-diabetic mice ( Figure 3D ). LpL activity in postheparin plasma did not correlate with the changes in mRNA levels or heparin-released muscle LpL activity (online-only Data Supplement IIIC). Taken together, insulin-deficient diabetes mellitus caused a marked reduction in postprandial triglycerides removal associated with reduced expression and activity of skeletal muscle LpL.
LpL Deficiency is Associated With Decreased Expression of PPARα and PPARδ
To explore how insulin deficiency affects LpL expression and activity, we studied LpL regulating factors. LpL expression in several tissues has been linked to peroxisome proliferatoractivated receptor (PPAR) expression and activation. [17] [18] [19] In our study, reduced LpL mRNA levels were associated with markedly lower PPARα mRNA in the skeletal muscle of diabetic mice after 3 weeks ( Figure 3E ). PPARδ mRNA was also decreased, whereas PPARγ was unchanged. We detected similar expression patterns of PPARs in the skeletal muscle after 8 weeks of streptozotocin-diabetes mellitus (online-only Data Supplement V).
LpL Expression in the Skeletal Muscle Modulates Diabetic Dyslipidemia
Fasted wild-type mice have a rapid turnover of plasma triglycerides. To study a more human-like model with less robust triglycerides lipolysis, we induced diabetes mellitus in heterozygous LpL knockout mice (Lpl +/− ). Our laboratory has previously reported that Lpl +/− mice on the ApoB overexpressing transgenic background have marked hypertriglyceridemia when treated with streptozotocin. 20 Streptozotocin treatment of Lpl +/− mice led to markedly increased plasma triglycerides (2.45±0.26 mmol/L) compared with nondiabetic Lpl +/− mice (1.389±0.316 mmol/L; Figure 4A & B) . Similar to wild-type mice, triglycerides secretion was not altered in streptozotocindiabetic Lpl +/− mice after P407 treatment and hepatic triglycerides content was reduced ( Figure 4C & D) . Again, after olive oil gavage streptozotocin-diabetic Lpl +/− mice displayed a significant impairment of triglycerides clearance ( Figure 4E ). The highest postprandial triglyceride levels in streptozotocintreated mice were identical to those of diabetic wild-type mice, but the rate of reduction between 4 and 6 hours was reduced compared with diabetic wild-type mice (4.2 mmol/l/h versus 7.7 mmol/L per h). These data suggest that impaired triglycerides clearance is the major cause for hypertriglyceridemia in streptozotocindiabetic mice. To test whether LpL overexpression would alter these diabetes mellitus-induced triglycerides changes, we studied postprandial lipemia in mice expressing human LpL primarily in skeletal muscle; the transgene is denoted muscle creatine kinase (MCK)-LpL. We note that the MCK-LpL transgene also leads to a small amount of LpL expression in the heart. 21 Streptozotocin-diabetic MCK-LpL/Lpl +/− mice had significantly lower fasting triglyceride levels compared with streptozotocin-diabetic muscle creatine kinase (MCK)-LpL. mice ( Figure 5A ). In addition, triglycerides clearance after olive oil gavage was significantly improved in streptozotocin-diabetic MCK-LpL/Lpl +/− mice compared with streptozotocin-diabetic Lpl +/− mice ( Figure 5B ). Therefore, LpL overexpression corrects diabetic dyslipidemia in insulindeficient mice. 
Discussion
In this report, we show that hypertriglyceridemia in insulindeficient diabetic mice is primarily because of changes in peripheral lipolysis and not because of changes in hepatic insulin signaling and hepatic triglycerides secretion. Similar to humans with either T1DM or T2DM, streptozotocin-induced diabetes mellitus in C57BL/6 mice led to a significant increase in plasma triglyceride levels. This observation was similar to that described by others. 22, 23 The primary lipoprotein abnormality in human diabetes mellitus is an increase in VLDL, which was reproduced in our streptozotocin-treated mice. There are 2 possible causes of diabetes mellitus-associated increase in triglycerides: elevated secretion of triglycerides from the liver or decreased clearance of triglycerides. 24, 25 (1) Hepatic overproduction of triglycerides has been attributed to compromised ApoB degradation because of the loss of insulin action, which eventually leads to increased VLDL assembly and secretion. 26, 27 Loss of insulin action also increases FFA flux to the liver and increases hepatic lipogenesis. 10 In addition, it has been suggested that hyperinsulinemia can drive de novo lipogenesis in the presence of increased plasma glucose levels and hepatic insulin resistance. 5 It should be noted that most human kinetic studies on triglycerides production are performed by injection of glycerol, which cannot separate de novo lipogenesis from substrate-driven triglycerides production. [28] [29] [30] [31] Therefore, these studies cannot determine the contribution of hepatic de novo lipogenesis and substrate-driven triglycerides production to hypertriglyceridemia. (2) Diabetic humans exhibit a marked defect in the clearance of postprandial lipemia. 32, 33 These findings are in accordance with reports of decreased LpL activity in postheparin plasma 34 and in skeletal muscle biopsies of diabetic patients. 35, 36 Accordingly, Taskinen et al 28 have shown that >20% of the hypertriglyceridemia in obese men is associated with increases in VLDL 1 secretion but almost 50% is related to impaired fractional catabolic rate. It is not clear, however, why only some patients develop hypertriglyceridemia with diabetes mellitus. For instance, in the ACCORD trial the average triglycerides level in all diabetic patients was 1.829 mmol/L (162 mg/dL), a level below the clinical threshold of hypertriglyceridemia (2.258 mmol/L [200 mg/dL]). 37 Therefore, it is likely that the minority of patients who develop severe hypertriglyceridemia have a defect in lipolysis.
Our objective was specifically to determine whether the effects of insulin signaling on hepatic triglyceride production found with genetic modifications were evident in mice with insulin deficiency. In our mouse model of streptozotocininduced diabetes mellitus, insulin deficiency did not lead to a significant reduction in hepatic triglycerides secretion nor did the lack of insulin actions reduce expression of genes involved in de novo lipogenesis. As reported by others, 13, 23 hepatic triglycerides content was significantly reduced and plasma FFA levels were increased in streptozotocin-diabetic mice. The reduced hepatic triglycerides content could be partially caused by increased fatty acid oxidation because mRNA levels of the rate limiting enzyme of β-oxidation CPT1-α were increased. Jourdan et al 23 have also noted an increase in CPT1-α and reported increased β-oxidation of palmitate in the livers of streptozotocin-treated mice. It is possible that without this increase in oxidation, more FFA would be converted to triglycerides leading to greater hepatic triglycerides secretion. Taken together, our data do not support the hypothesis that insulin deficiency reduces triglycerides production and suggests that the hypertriglyceridemia in streptozotocin-diabetic mice is primarily because of a catabolic defect.
No model of diabetes mellitus is perfect but the streptozotocin model used in our studies is the one recommended by the National Institutes of Health Animal Models of Diabetic Complications Consortium. 38 The low dose streptozotocin leads to partial insulin deficiency that causes hyperglycemia but allows sufficient insulin to prevent ketoacidosis and early death. This model does not lead to obesity and peripheral insulin resistance as would be seen in T2DM. In fact, streptozotocin-treated mice have reduced adipose stores and the effects of insulin deficiency in obese animals are likely to be different. Specifically, greater adipose would be expected to lead to greater FFA release and high plasma FFA levels that are likely to drive greater liver production of triglycerides. Nonetheless, we think that streptozotocin treatment is more likely to reflect human disease than models that lead to nonphysiological modification of gene expression.
Independent of insulin action on hypertriglyceridemia, glucose also generates a signal that may modulate triglycerides production and triglycerides clearance. 39, 40 Glucose controls the expression of key genes involved in energy metabolism through the carbohydrate response element-binding protein.
Carbohydrate response element-binding protein binds to the promoter region of glycolysis-associated (eg, pyruvate kinase) and lipogenesis-associated genes 40 and may drive diabetic hypertriglyceridemia by increasing transcription of de novo lipogenesis genes. 41 Glucose may also exert direct effects on triglycerides clearance. Hyperglycemic conditions downregulate LpL activity in humans 42, 43 and in cultured human adipocytes. 44 This suggests that hyperglycemia per se contributes to the decreased LpL activity and subsequent hypertriglyceridemia in poorly controlled diabetes mellitus. Until recently it has been difficult to separate the effects of hyperglycemia versus defective insulin actions on diabetic hypertriglyceridemia because glucose-reducing interventions were achieved by either insulin administration or by improved insulin sensitivity. By inhibiting sodium glucose cotransporter 2 in the kidney, which leads to increase glucose output in the urine, we were able to reduce plasma glucose levels without affecting insulin levels in streptozotocin-diabetic mice, although we cannot rule out changes in insulin signaling. 45 Both the pharmacological inhibition by dapagliflozin and antisense oligonucleotide-mediated inhibition of sodium glucose cotransporter 2 significantly reduced plasma glucose levels in streptozotocin-diabetic mice, but did not change plasma triglyceride levels. More importantly, hepatic triglycerides secretion was similar in streptozotocin-diabetic mice with normalized glucose levels making it unlikely that increased glucose levels contribute substantially to hypertriglyceridemia in streptozotocin-diabetic mice.
Postprandial lipemia is markedly increased in humans with diabetes mellitus. [46] [47] [48] Accordingly, in our study streptozotocin-diabetic mice displayed increased plasma triglyceride levels and delayed clearance after gavage with olive oil. LpL is the rate-limiting enzyme for the hydrolysis of triglycerides in circulating chylomicrons and VLDL. LpLmediated hydrolysis products, fatty acids, and monoacylglycerol, are taken up by the tissues and stored as neutral lipids in WAT, or oxidized in skeletal and cardiac muscle. 15, 16 LpL is regulated at the transcriptional, post-transcriptional, and post-translational level in a tissue-specific manner. 49 Food-intake decreases LpL activity in skeletal muscle and increases it in WAT. Fasting increases LpL activity in the skeletal muscle and heart, and decreases LpL in the WAT. We detected a significant decrease of LpL gene expression in the skeletal muscle, heart, and WAT after 3 and 8 weeks of streptozotocin-diabetes mellitus. Accordingly, heparinreleasable LpL activity in the skeletal muscle, heart, and brown adipose tissue of streptozotocin-diabetic mice was significantly reduced; all these tissues are major sites for LpL synthesis. 16, 50 We were unable to study heparin-releasable LpL activity in WAT because streptozotocin-diabetic mice were lipodystrophic, but the reduction in total adipose LpL, as we have shown before, likely contributes to the defective lipolysis. 51 Therefore, these results show that decreased LpL activity in brown adipose tissue, skeletal muscle, and heart correlates with hypertriglyceridemia in streptozotocindiabetic mice. Increased apoC-III that we detected in plasma might also affect lipolysis or the changes in lipoproteins associated with LpL deficiency and diabetes mellitus might have caused a secondary increase in apoC-III. Perhaps this ApoC-III increase is also responsible for the defect in lowdensity lipoprotein uptake previously reported in diabetic low-density lipoprotein receptor knockout mice. 52 LpL activity has been studied previously in diabetic humans and rodents. In patients with T2DM LpL mRNA, protein expression and activity were significantly decreased in skeletal muscle. 35, 36 Conflicting results have been reported in studies of LpL activity in the heart and the skeletal muscles in streptozotocin-treated rodents. Both decreased 53 and increased 54 activity levels have been observed. The reported differences might relate to the length as well as severity of diabetes mellitus and methodological differences, for example, measurement of LpL activity in homogenized tissue versus heparin-releasable LpL activity and data obtained from mice versus rats. In fact, although we found reduced heparin-releasable LpL activity in the muscles of diabetic mice, LpL activity measurements of tissue homogenates were not significantly different (data not shown).
In contrast to the decreased LpL activity in the skeletal muscle, postheparin lipase activity in the plasma did not differ between our streptozotocin-diabetic and control mice (2.4±0.16 μm FFA/mL per h versus 2.41±0.10 μm FFA/mL per h, respectively). Similarly, Pollare et al 36 did not detect differences in postheparin LpL activity in the plasma of T2DM patients but reported decreased LpL activity in the skeletal muscle of these patients. It is questionable whether total postheparin plasma LpL activity accurately reflects changes in total lipolytic activity.
To explain the reduced levels of LpL, we tested gene expression levels of 2 well-known transcriptional regulators of LpL, PPARα, and PPARδ. Schoonjans et al 17 showed that the expression of LpL is regulated by PPARα (and PPARγ), which interact with a response element in the LpL promoter. PPARδ agonist treatment increases LpL mRNA and protein levels in skeletal muscle cells 18 ; PPARδ also increases expression of the LpL inhibitor Angplt4, 55 which was not significantly decreased in our studies. Several clinical studies suggested that the triglyceride-lowering action of PPARα agonists is associated with an increase in LpL activity. [56] [57] [58] Others have shown that PPARα and PPARγ agonists enhance LpL expression and activity in human macrophages. 19 Considering these studies, we hypothesized that decreased LpL expression in the skeletal muscle of streptozotocin-diabetic mice was because of a decreased transcription of PPARα. Insulin enhances the transcriptional activity of PPARα in vitro. 59 We found reduced expression of PPARα and PPARδ with insulin deficiency in skeletal muscle of streptozotocin-diabetic mice. We hypothesize that the lack of insulin leads to a decrease primarily of PPARα followed by a decrease of LpL expression in the skeletal muscle. Surprisingly, we noted reduced CD36 expression in skeletal muscle of diabetic mice. Although one might expect that myocytes would shift to greater fatty acid oxidation with insulin deficiency, we suspect that muscle metabolism in our animals was heavily dependent on glucose, but with glucose uptake primarily via noninsulin-dependent and non-GLUT4-dependent pathways.
To study if changes in LpL expression would actually modify diabetes mellitus-induced hypertriglyceridemia, we studied mice with a heterozygous deletion of the LpL gene (as homozygous LpL knockout mice are not viable). Lpl +/− mice exhibited marked hypertriglyceridemia after induction of streptozotocin-diabetes mellitus. More importantly, triglycerides secretion was again not significantly different in streptozotocin-diabetic Lpl +/− mice but triglycerides clearance was delayed after gavage with olive oil. Similar to our diabetic Lpl +/− mice, human diabetic carriers of dysfunctional LpL alleles are at risk for severe lipemia. 60 We hypothesized that increasing LpL expression would ameliorate diabetic hypertriglyceridemia in our animal model. Constitutive skeletal muscle-specific expression of human LpL eliminated hypertriglyceridemia in the streptozotocin-diabetic Lpl +/− mice and triglycerides clearance after olive oil gavage was reduced to almost normal nondiabetic levels. We presume that the constitutive expression of LpL increased lipolysis and VLDL remnant removal. Similarly, Shimada et al 61 reported that diabetes mellitus-mediated increases in triglycerides were eliminated by overexpression of LpL in streptozotocin-diabetic C57BL/6 mice. Thus, a major regulator of circulating triglycerides in diabetes mellitus is LpL action regardless of changes in liver triglycerides production.
In conclusion, hypertriglyceridemia in insulin-deficient mice is primarily caused by a defect in peripheral lipolysis and not by an increase in hepatic triglycerides secretion as suggested by mouse models of impaired hepatic insulin signaling. Most humans with diabetes mellitus do not have marked hypertriglyceridemia. However, humans, like mice, that have a defect in LpL regulation are most likely to develop severe hypertriglyceridemia with diabetes mellitus. 60, 62, 63 However, humans with robust LpL activity are likely to be protected from hypertriglyceridemia regardless of their degree of insulin deficiency or resistance. Therefore, methods to augment peripheral triglycerides lipolysis are likely to be most efficacious in the treatment of diabetes mellitus-induced hypertriglyceridemia.
